1119 ET - Merck KGaA's acquisition of SpringWorks Therapeutics for $47 per share, or $3.9 billion in total, carried an underwhelming price tag to say the least, Evercore ISI analysts say in a research note. The analysts expected an agreement to price shares in the $60s, which would have still been highly attractive for the buyer, they said. The final deal price net of cash represents just two times the company's consensus peak sales, the analysts said, adding they can't recall such a low multiple for a company not in distress. "Hopefully this transaction is not a broader indictment on the state of biotech M&A amidst a difficult backdrop," the analysts say. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
April 28, 2025 11:20 ET (15:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.